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Abstract

Congenitalcytomegalovirus (CMV) 1s the most common virus spread
in utero from mother to fetus, leading to more long-term problems and
childhood deaths than other conditions such as Down syndrome, fetal
alcohol syndrome, pediatJic HIV/AIDS, or neural tube defects. The
maprity of congenital CMV infec:ions are primary infections in which
the mother acquires !he infectiondunng pregnancy. Currenttreatmem
options for CMV mfect10n are available, but there IS limited data on
safety and effecoveness in pregnant mothers and neonates. Prevention by screening tor CMV IS associated with a high cost, and vaccines
are currently unavailable. Studies show that education and behavioral
modlficatlOns are effecove ways to lower the nsk of CMV 1nfecb0n
in neonates, making pnmary prevention by these methods cntJCal to
reducing the transm1Ss10n of CMV infection.

An estimated 60 percent of women of child-bearing age in the U.S. are
infected with CMV.5Of the remaining 40 percent of women who have
never been infected with CMV, approximately 1-4 percent will acquire
a primary infection while pregnant. 1 A mother acquires CMV by coming
into contact with urine, saliva or genital secretons of an infected person.5Seronegative mothers with a CMV-infected child typically become
infected within one year after their child acquires a CMV infection, and
up to 70 percent of children in group childcare acquire CMV. 6 CMV
infection can occur one of two ways dunng pregnancy. The mother can
either receive a primary infection, 1n which the mother acquires the virus
dunng pregnancy, or the infection can result from a secondary infection
in which a dormant virus reactivates. Primary nfections are the cause for
the mapnty of infants who are born with a congenital CMV infection, and
secondary infections account for only about 2 percent of congenital CMV
infections.7 Women can infect the fetus during any tnmester or perinatally via contact with genital secretions at birth and/or from breast milk. 5

Overview
Cytomegalovirus is the most comrron virus spread in utero from mother
to fetus within the U.S. Every year, approximately 30 ,000 infants are born
within the U.S. with congenital cytomegalovirus (CMV). Eighty percent
of these infants will be asymptomatic, but the remaining infants will likely
develop neurologic sequelae, equating to more than 5,000 children each
year who are born with or develop oermanent disabilities and approxi-

A mapnty of children born with congenital CMV never experience any
problems or symptoms, but about one in every 750 children born with
CMV suffer from permanent problems due to the infection. Short-term effects of congenital CMV infection include premature birth, hepatomegaly,
spfenomegaly, }3undice, purpura, petechia, pneumonitis and seizures.
Permanent outcomes consist of microcephaly, vision loss, hearing loss,
learning disabilities, motor disabilities, seizures, cerebral palsy and, in

mately 400 deaths due to CMV. '' CMV leads to more long-term problems

some cases, death. •.ll.q Almos t all adults have been exposed to CMV,
but a healthy adult with a normal immune system will likely be asymp-

and childhood deaths than other conditions such as Down syndrome, fetal
alcohol syndrome, pediatJic HIV/ADS, or neural tube defects. Unfortunately, only 14-22 percent of women are aware of CMV, and fewer than half of
obstetricians talk to expectant mothers about the wus. 1 ~ A member of the
herpes virus family, CMV lives within its host for the duration of the hosrs
lifetime, although its acbv11.y is usually dormant. 4
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Figure t U.S. Children Born with or Developing Long-Term Medical
Conditions Each Year'(Adaµed frorr CDC.gov)

tomatic. Those at increased risk for infection include babies born to
women who have a first-time CMV infection dunng pregnancy, pregnant
women who work with infants and children, and persons with weakened
immune systems. 10 Hearing and v1s1on loss may not develop until one
to two years after birth, so the Centers for Disease Control and Prevention (CDC, Atlanta, Ga.) recommend that seropositive, asymptomatic
children have their hearing and vision monitored regularly. It IS estimated
that one-third of sensorineural hearing loss in children is due to CMV
infection.9
Screening
Currently, there are no systematic screening programs in place to
identify patients in at-risk groups so that educational programs can be
tailored to patient's specific test results, allowing for appropriate primary,
secondary and tertiary prevention methods and behavior modification. A
screening program offered at the beginning of pregnancy could identify
women who are seronegative and provide an opportunity for primary
preventJon strategies such as educaoon and behavior modification to
prevent seroconversion during pregnancy.7 Screening at the start of
pregnancy uses serological tests of urine, saliva or tissue samples to
1denhfy CMV lgG and lgM antibodies. The presence of antibodies 1ndi·
cates CMV infection but cannot identify whether an infection 1s primary
or recurrent. This may cause unnecessary pabent anxiety because
primary infections are more likely to cause compllca.tlons than recurrent
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infections. 11 If a mother has already seroconverted, additional screenings
which use ultrasound can 1dent1fy fetuses that express cerebral complications, allowing secondary prevention strategies to be implemented
with a goal of prevenDng comphcatJons due to infection. Ultrasound
screening alter mother seroconvers1on 1s not very effective because
most fetal defects cannot be identified until the last trimester. screening
meU1ods also can IJe used to tC1rgel LerliC1ry preve11liu11 strntegies such
as early management of neurological sequelae. One method of tertiary
screening is to use serological tests at the beginning and throughout
pregnancy to give a prenatal diagnosis of the infant. Another method of
screening is to perform a serological test of urine or dried bloods pots
upon birth to identify asymptomatic infants. By identifying asymptomatic
infants at birth that are seropositive, closer monitoring of neurological development can help manage subsequent sequelae that may not
develop until later m infancy. Also, early identification of hearing loss
through routine screening at birth may improve the prognosis for children
with CMV. Testing of dned bloodspots could easily be incorporated into
state newborn screening programs, which are already in place; however, dned blood tests are not as sensitive as urine tests. Limitations of
tertiary preventron include m1n1mal benefits for infants with severe neural
complications and tne lack of programs currently in place for continuing the monrtonng of seropos1tive infants to help identify and manage
potential complications. A mapr drawback to all types of screening 1s the
cos t associated with testing all pregnant women and neonates. 7·12
Treatment
Current treatments for CMV are lacking safety profiles in pregnant women due to severe side effects and have no proven efficacy in preventing
transmissron to the fetus. Ganciclovir is a treatment option for congenital
CMV infection but is limited to only the most severe cases due to its
adverse event profile. It is an anti-viral agent that is used in an attempt to
prevent hearing loss in infants. In a randomized, controlled trial, patients
who received ganciclovir did not have any further hearing deterioration
at six months. 41 percent of patients not receiving ganc1clov1r therapy
demonstrated heanng detenorat1on (adjusted P < 0.01 ). However, the
mapnty of paoonts who received ganciclovir therapy experienced significant hematologrcal toxrciry. Furthermore, its long-term safety has not
been estabhshed in ch11dren. 13
Another treatment option being explored is intravenous human immunoglobulin (IVIG) administration, but it is not currently approved for use in
the treatment of CMV. Limitations in implementing IVIG therapy include
a limited supply and cost of treatrrent. 6•14 lmmunoglobulin therapy is still
being studied in clinical trials and has emerged as an off-label use for
CMV among physicians, but little is known about its toxicity.
Prevention
A vaccine 1s the most promrsing way to fight congenital CMV; however,
a vaccine is not yet commercially available in the u.s.s.a It is estimated
that with proper funding, a vaccine could be developed within seven
years.2A vaccine could be given in childhood or adolescence, and pnor
immunrzallon could prevent a pnmary CMV infection in women dunng
pregnancy.5 By implementing vaccination, it is estimated that approximately $4 b1lhon 1n health care costs could be saved every year. 2 There
currently are several vaccines in development.> Novartis and AlphaVax

25

THE P HAAMAcr AND WELL NEss REv 1Ew

Volume two, Issue one

currently are developing a single-cycle particle vaccine that carries RNA
encoding three antigens from the CMV virus. The vaccine will target
adolescent women. 15 Sanofi Pasteur recently finrshed phase II 1rials of a
molecule s1m11ar to Novartis' and found that the vaccine decreased the
incidence of maternal and congenital CMV 1nfectron {no P value provided).16 Vrcal also is developing a CMV vaccine , CyMVectin™, to prevent
sel(x:;onversiu11 prior to pregnC111cy. CyMVeclirr iS set to enter pt1C1se I lril:llS
with the approval of their lnvestigational New Drug Application. 17 The
biggest limitation in vaccine implementation is that several studies have
shown that a previously infected person can become re-infected with a
new strain of the virus, thus decreasing the lik9lihood that a single protein
can provide immunity for all strains of the virus. 13
Because vaccines are currently unavailable and treatment strategies
are lacking safety profiles , education on preventing the disease through
behavror modification is critical in preventing the transmrssron of the virus
and subsequent infection in neonates. 6
The American College of Obstetrics and Gynecology recommends counseling about CMV prevention by emphasiZing hygienic practrces.8 There
are many preventative strategies that can be employed by the patient to
reduce the nsks of acquiring or transmitting the disease. Both protective
and avoidance behaviors need to be taught in the prevention against
CMV (Table 1). Protective behaviors include frequent hand-washing alter
diaper changes, feeding or bathing a child, and handling children's toys
as well as using gloves when cleaning surfaces that come in contact
with saliva or urine. Avoidance behaviors include eliminating salivary
contact by not sharing food, toothbrushes, utensils or pacifiers. Horizontal
transmission of CMV is very common in childcare settings due to the high
incidence of children under 30 months who actively shed CMV in their
urine and saliva. Contact in the day-care setting can increase the risk of
acquiring CMV by up to 25 fold.9 It is estimated that those exposures can
cause up to 12,000 cases of newborn infections and neurologic damage. 19
Table 1: Behavior modilicalions to prevent transmission ot CMV~'
Ways to Reduce CMV Transmission
Wash hards thoroughly with warm soap aoo water
• Alterdia~r cha nges
· Alter feeding or oothing the child
· Alter wifing a runny nose or drool
• Alter haoolingchildren's toys
Clean surfaces that corm into contact with the ch:ld
• Countertoµ;
· Toys
• Surfaces in contact with urine and saliva
Limit sharing of oqects in contact with saliva and/or urire
· Cuµ;
· Utensils
· Food
· Plates
• Toothtrushes
· Towels aoo wast-cloths

Do not klSS on or near the mouth
Aduks should not PJt a child's ~cifier 1n their rrouth
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A study was conducted to test the efficacy of preventative methods in
child-to-mother transmission of CMV mpregnant and non-pregnant mothers with children enrolled at 124 day-care centers mVirginia from 1999
to 2001. The women were randomized into three groups. a control group,
a partlal intervention group and a full intervention group. For all three
groups, the women, all children in the home and the fathers had urine
amJ saliva collectl:!d !:!very Uuel:! r11u11U1s ror CMV scrl:!l:!11i11y ror a total or
12 months or until delivery. The control group was only given basic information aoout CMV, and seroconversion results were not revealed. The
partial intervention group was given information about the virus as well as
a video presentation that focused on how to prevent transmission. This
group was also taught aoout protective behaviors such as proper handwashing, wearing gloves when changing a diaper, and avoiding salivary
contact with children through either sharing food and drink or kissing on
the mouth. Latex gloves were given to the mothers to use during diaper
changes as well as liquKI soap. This group also underwent CMV screening , but only the mothe(s initial serum status was revealed. The full
intervention group was given all of the same educational informatJon, as
well as preventJOn measures, given to the partial intervention group. The
full intervent10n group also received CMV culture screening every three
months but were told the in1bal results of the mother's and the ch1k:l's
screening. If a child was not shedding at enrollment, mothers were educated that there was a high probability their child could begin shedding
the virus at any time. An interim analysis showed that half of the children
who initially were not shedding began to shed the virus at some point
during the study; therefore, all mothers enrolled in the partial intervention
group were re-assigned to the full intervention group. The results of this
study found that intervention in pregnant women may have lowered the
risk of acquiring CMV by as much as 85 percent. Pregnant women were
more motivated to incorporate the interventions into their daily lives. The
women were more attentive, took notes and asked questions compared
to their non-pregnant counterparts who seemed less engaged.6
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